TABLE 1.
Sample characteristicsa
| Region(s) of cohort site (country) |
Study type | Study purpose | Yr(s) | No. of samples |
Mean age (yr) of subjects (CI) |
% female/ % male |
Reference | Classification of sera |
|---|---|---|---|---|---|---|---|---|
| Bahia (Brazil) | Cross-sectional | Zika virus surveillance | 2015–2016 | 28 | 41 (34, 47) | 54/46 | 8 | CHIKV |
| Rio de Janeiro (Brazil) |
Prospective, longitudinal |
Zika virus/CHIKV antibody kinetics |
2016 | 36 | 41 (29, 53) | 33/67 | 6 | CHIKV |
| Loreto, Piura, Lambayeque (Peru) |
Prospective | Malaria surveillance | 2018 | 21 | 38 (28, 47) | 55/45 | NA | MAYV |
| Junín, Cusco, Loreto (Peru) |
Prospective | Malaria surveillance | 2001–2004 | 16 | 17 (10, 25) | 50/50 | NA | MAYV |
a
CI, 95% confidence interval; NA, not available; CHIKV, Chikungunya virus; MAYV, Mayaro virus. Sampling and testing were conducted in accordance with IRB approval numbers 1.408.499 and UPCH104562 and CAAE approval number 58782016.8.1001.5249.